These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16141103)

  • 1. Standardized doses of epoetin alfa for hemodialysis patients.
    Nguyen TV; Iacovino LA
    Am J Health Syst Pharm; 2005 Sep; 62(18):1867. PubMed ID: 16141103
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis.
    Barnett AL; Crémieux PY
    Pharmacotherapy; 2003 May; 23(5):690-3; discussion 693-4. PubMed ID: 12741447
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching from i.v. to s.c. epoetin in hemodialysis patients.
    Knauss MD; Walton T; Macon EJ
    Am J Health Syst Pharm; 2002 Sep; 59(18):1783-4. PubMed ID: 12298119
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy.
    Itri LM
    Nephrol Dial Transplant; 2001 Dec; 16(12):2289-93. PubMed ID: 11733616
    [No Abstract]   [Full Text] [Related]  

  • 5. Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.
    Einarson T; Machado M; Walker J; Iskedjian M
    Curr Med Res Opin; 2007 Jul; 23(7):1571-3; author reply 1573-4. PubMed ID: 17637205
    [No Abstract]   [Full Text] [Related]  

  • 6. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
    Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia in the nursing homes: a complex issue.
    Morley JE
    J Am Med Dir Assoc; 2012 Mar; 13(3):191-4. PubMed ID: 22261540
    [No Abstract]   [Full Text] [Related]  

  • 8. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure.
    Conlon PJ; Kovalik E; Schumm D; Minda S; Schwab SJ
    Ren Fail; 2000; 22(4):435-44. PubMed ID: 10901181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
    Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
    Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients.
    Minutolo R; Borzumati M; Sposini S; Abaterusso C; Carraro G; Santoboni A; Mura C; Filiberti O; Santoro D; Musacchio R; Imperiali P; Fiorini F; De Nicola L; Russo D
    Am J Kidney Dis; 2016 Jul; 68(1):170-2. PubMed ID: 26879099
    [No Abstract]   [Full Text] [Related]  

  • 14. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
    JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios.
    Raymond CB; Wazny LD; Vercaigne LM; Lesperance EM; Skwarchuk DE; Bernstein KN
    CANNT J; 2008; 18(1):39-43. PubMed ID: 18435363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of once-weekly and three-times-weekly dosings of epoetin alfa in chemotherapy patients: problems of study design and interpretation.
    Nguyen TV; Trinh GN
    J Clin Oncol; 2002 Feb; 20(3):878. PubMed ID: 11821478
    [No Abstract]   [Full Text] [Related]  

  • 17. Administration of Epoetin alfa. Case study of the anemic patient.
    Cutler M
    ANNA J; 1997 Aug; 24(4):459-65; quiz 466. PubMed ID: 9325701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of epoetin dose on hematocrit.
    Cotter D; Zhang Y; Thamer M; Kaufman J; Hernán MA
    Kidney Int; 2008 Feb; 73(3):347-53. PubMed ID: 18004296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding epoetin use: databases or clinical trials?
    Roger SD
    Nephrology (Carlton); 2007 Apr; 12(2):118-9. PubMed ID: 17371331
    [No Abstract]   [Full Text] [Related]  

  • 20. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.
    Goodkin DA; Gimenez LF; Graber SE; Van Stone JC; Egrie JC; Okamoto DM
    Clin Nephrol; 1999 Jun; 51(6):367-72. PubMed ID: 10404697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.